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ABSTRACT
Aims Here we explore the presence of mediator 
complex subunit 12 (MED12) exon 2 and telomerase 
reverse transcriptase (TERT) promoter hotspot mutations 
in complex fibroadenomas (CFAs) of the breast.
Methods The stromal components from 18 CFAs 
were subjected to Sanger sequencing of MED12 exon 2 
and the TERT promoter hotspot loci. The epithelial and 
stromal components of two MED12 mutated CFAs were 
subjected to laser capture microdissection, and Sanger 
sequencing of MED12 exon 2, TERT promoter and 
PIK3CA exons 9 and 20, separately.
Results MED12 exon 2 mutations were identified in the 
stroma of 17% of CFAs. The analyses of epithelial and 
stromal components, microdissected separately, revealed 
that MED12 mutations were restricted to the stroma. No 
TERT promoter or PIK3CA mutations in exons 9 and 20 
were detected in analysed CFAs.
Conclusions Like conventional fibroadenomas, MED12 
exon 2 mutations appear to be restricted to the stromal 
component of CFAs, supporting the notion that CFAs are 
stromal neoplasms.
INTRODUCTION
Fibroadenomas (FAs) of the breast are a group of 
benign biphasic neoplasms consisting of a prolif-
eration of both epithelial and stromal compo-
nents.1 After the seminal publication by Lim et al,2 
describing mediator complex subunit 12 (MED12) 
exon 2 mutations in approximately 60% of FAs, 
our group and others have not only confirmed 
the presence of these mutations in FAs, but also 
demonstrated that they are restricted to the stromal 
component of these lesions.2–5 MED12 exon 2 
mutations have also been detected in other fibroep-
ithelial neoplasms, including phyllodes tumours 
(PTs), where these mutations are present in 88% 
of benign, in 78% of borderline and in 8% of 
malignant PTs.5–8 In addition, our group initially 
described the presence of telomerase reverse tran-
scriptase (TERT) promoter hotspot mutations in 
PTs,7 which have been confirmed to increase in 
frequency from benign to malignant PTs and to be 
vanishingly rare in conventional FAs.9–11
FAs comprise histologic variants, including juve-
nile fibroadenoma, cellular FAs and complex fibro-
adenomas (CFAs), which display different histologic 
features and variations in their clinicopathologic 
characteristics. A subset of FAs, characterised by 
abundant myxoid matrix and hypocellular stromal 
component, was previously categorised as myxoid 
fibroadenomas (MFAs) as per fourth edition WHO 
classification.12 These lesions were reported to lack 
MED12 exon 2 mutations in the stromal compo-
nent, and to harbour recurrent mutations in TP53, 
PIK3R1, ERCC5 and PIK3CA in the epithelial rather 
than the stromal component.13 Importantly, in one 
case of MFA included in Lozada et al,13 a muta-
tion affecting PRKAR1A was detected in the stromal 
component, and the case was subsequently reclassified 
as a myxoma. Per fifth edition WHO classification of 
breast neoplasms,1 CFA is a variant of fibroadenoma 
that contains one or more of the following histological 
findings: cysts >3 mm, sclerosing adenosis, epithelial 
calcifications and papillary apocrine metaplasia. As 
compared with conventional FAs, CFAs have more 
abundant epithelial components sharing histological 
features of proliferative fibrocystic disease of breast 
and less characteristic neoplastic stroma. An increased 
relative risk (RR) of subsequent invasive breast carci-
noma was reported for patients with CFAs (RR 3.10; 
95 % CI 1.9 to 5.1) in comparison to patients with 
conventional FAs (RR 2.17; 95 % CI 1.5 to 3.2).14 
Other studies, however, have indicated that CFAs 
may not result in increased breast cancer risk beyond 
the presence of other established risk factors such as 
proliferative disease or atypical epithelial hyperplasia 
of breast. The clinical behaviour of CFAs, however, 
remains contentious, and the current recommenda-
tion is to manage patients with CFA with a conser-
vative approach, similarly to the approach employed 
for the management of women with conventional 
FAs.15 16
The genetic underpinning of CFAs, whether 
the abundant epithelial component contributes to 
the tumorigenesis or whether they are genetically 
related to conventional FAs or PTs is unclear. Here 
we conducted an exploratory analysis to determine 
whether MED12 exon 2 and TERT promoter hotspot 
mutations would be present in CFAs. Furthermore, 
given our previous findings that PIK3CA hotspot 
mutations were present in PTs without FA- like areas 
and in a subset of FAs, classified as MFAs in the prior 
(fourth edition) WHO classification,8 12 13 in addition 
to the MED12 exon 2 and TERT promoter hotspot 
mutations, we also assessed the presence of mutations 
in exons 9 and 20 of PIK3CA in separate epithelial and 
stromal components of two CFAs subjected to laser 
capture microdissection (LCM).
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Following institutional review board approval, slides and 
formalin- fixed paraffin- embedded (FFPE) tissue blocks of 24 
CFAs from 23 adult patients were retrieved from the archives 
of the Department of Pathology of Memorial Sloan Kettering 
Cancer Center (New York, USA). All cases were reviewed by 
nine breast pathologists (APMS, FP, ME, TMD, MPM, HYW, 
EB, JSR- F and HZ) and were reclassified according to the WHO 
criteria fifth edition (2019).1 A diagnosis of CFA was rendered 
when at least one or more complex features were present (ie, 
cysts >3 mm, sclerosing adenosis, epithelial calcifications and 
papillary apocrine metaplasia). Eighteen CFAs (from 17 anony-
mised patients) were included in this study on a consensus diag-
nosis being rendered. All cases are unique to this study, and none 
has been previously reported.
Tumour microdissection and sequencing
Eight micrometre thick FFPE representative histological sections 
of 18 CFAs were microdissected under a stereomicroscope 
(Olympus SZ61) to ensure a stromal cell content >80%. DNA 
was extracted using the DNeasy Blood and Tissue Kit (Qiagen) 
according to the manufacturer’s instructions. Sanger sequencing 
was used for the assessment of mutations affecting MED12 exon 
2 and TERT promoter hotspots in the stromal components of 18 
CFAs. Sanger sequencing and PCR amplification methods were 
performed as previously described17 and are detailed in online 
supplemental methods and table S1.
To define whether the mutations affecting the exon 2 of 
MED12 would be restricted to the stroma or would also be 
present in the epithelial component in the MED12 mutated 
cases, representative samples from these tumours were subjected 
to LCM to obtain the epithelial and stromal components sepa-
rately (online supplemental methods). Due to the limited mate-
rial available in one of the cases (CFA7), LCM was performed 
in two (CFA18 and CFA22) CFAs harbouring MED12 exon 2 
mutations. DNA samples from the epithelial and stromal compo-
nents were subjected to Sanger sequencing of MED12 exon 2, 
TERT promoter hotspots and PIK3CA exons 9 and 20. Sequence 
electropherograms of the forward and reverse strands were anal-
ysed using Mutation Surveyor (SoftGenetics) and the mutations 
identified were manually curated. All analyses were performed 
in duplicate.
RESULTS
Our study included 18 CFAs from patients with a median age of 
48 years at diagnosis (range 33–82 years, (online supplemental 
table S2). All CFAs harboured at least one complex feature, 
such as sclerosing adenosis or fibrocystic changes (figure 1A and 
online supplemental table S2). Fibrocystic changes including 
usual ductal hyperplasia without atypia, apocrine metaplasia, 
columnar cell changes, cyst formation and stromal fibrosis were 
identified in all CFAs, and sclerosing adenosis were present in 
the adjacent breast tissue in 13 (72%) cases. Based on the data 
retrieved from the pathology reports, concurrent ductal carci-
noma in situ (67%, 12/18), invasive ductal carcinoma (22%, 
4/18), invasive lobular carcinomas (6%, 1/18), lobular carcinoma 
in situ (11%, 2/18) or atypical ductal hyperplasia (6%, 1/18) 
were identified in the breast tissue away from CFAs included in 
this study.
MED12 exon 2 mutations were identified in the stromal 
component of 17% (3/18) of CFAs (figure 1B and online supple-
mental table S2). Two CFAs harboured the hotspot p.G44S 
(c.130G>A) and one case harboured the pathogenic p.L36R 
(c.107T>G) MED12 mutations (figure 2A–C and online supple-
mental table S3. No differences in the histologic and clinical 
features of the CFAs, according to the presence or absence of 
MED12 mutations were found online supplemental figure S1 and 
table S2. No TERT promoter hotspot mutations were detected 
in the CFAs analysed (figure 1B, online supplemental table S2).
In CFA18 and CFA22, where the epithelial and stromal 
components were successfully separated, Sanger sequencing 
analysis revealed that the MED12 mutations (p.G44S) were 
exclusively restricted to their respective stromal components. 
No MED12 mutations were found in the epithelial component 
of the CFAs (figure 2D and online supplemental table S4). No 
TERT promoter hotspot mutations or PIK3CA mutations in 
exons 9 or 20 were found in either the epithelial or stromal 
component of the CFAs subjected to LCM.
DISCUSSION
CFAs are a variant of FAs12 and comprise 22.7% to 40.4% of 
diagnosed FAs.14 18 Often clinically overlooked, CFAs tend to 
occur in patients older than those with conventional FAs15 18 
with an average size of half of other FAs.15 Histologically, 
the presence of epithelial alterations overlapping with fibro-
cystic changes inside the lesion is characteristic of this FA 
subtype. Tubular adenoma of breast, which is a rare epithelial 
proliferation arising from the terminal duct lobular unit, is 
occasionally in the differential diagnosis due to the presence 
of prominent sclerosing adenosis inside the CFA.19 Although 
some studies suggest that CFAs carry a slightly increased risk 
of subsequent development of breast cancers comparing to 
general population,14 others did not confirm this risk.15 16
The exploratory, hypothesis generating analysis performed 
here revealed that, akin to conventional FAs, a subset of CFAs 
harbour pathogenic mutations in MED12 exon 2, although 
at a lower frequency (17% CFAs vs up to 65% conventional 
FAs).5 17 These findings support the notion that while CFAs 
and conventional FAs are morphologically and, to a certain 
extent, clinically separate entities, they share similar genetic 
alterations in MED12 in a subset of cases, in agreement with 
what was reported by Lien et al.20 Due to the rich nature 
of epithelial component and its integral growth mixed with 
stromal components, it is technically challenging to obtain 
adequate amount of DNA from the separate components 
in CFAs by LCM. We successfully assessed mutations in 
MED12 exon 2 and TERT promoter loci in the separately 
laser microdissected epithelial and stromal components of 
Figure 1 Histologic features and frequency of MED12 exon 2 
and TERT promoter mutations in complex FAs of the breast. (A) 
Representative H&E micrograph of a complex FA displaying apocrine 
metaplasia (bottom right) and sclerosing adenosis (top right), scale 
bar, 2 mm. (B) Frequency of MED12 exon 2 and TERT promoter hotspot 
mutations in the stromal component of 18 CFAs included in this study. 
CFAs, complex fibroadenomas; FAs, fibroadenomas; MED12, mediator 
complex subunit 12; TERT, telomerase reverse transcriptase.
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two CFAs. These cases were also subjected to Sanger analysis 
of PIK3CA exons 9 and 20. Given that MED12 mutations are 
restricted to the stromal component, CFAs, akin to conven-
tional FAs, likely constitute stromal rather than fibroepithe-
lial neoplasms. No PIK3CA mutations in exon 9 and 20 were 
identified in these cases, consistent with previous observa-
tions derived from the analysis of fibroepithelial lesions 
harbouring MED12 mutations.10
Our study has limitations. Due to limited archived FFPE 
tissue availability, we restricted our analysis to specific genetic 
alterations. Our analysis was restricted to the mutations 
affecting MED12 exon 2, TERT promoter hotspot mutations, 
and in two MED12 exon 2 mutated cases, also PIK3CA exons 
9 and 20. Although our findings support the notion that 
MED12 exon 2 mutations do not constitute the main driver 
of CFAs, we cannot rule out that there are other genes which 
may play a role in the biology of CFAs. Moreover, due to the 
size of our cohort and rarity of recurrent events, our study 
may have a limited power to assess the significance of the 
presence of MED12 exon 2 mutations in the stromal compo-
nent of CFAs. All CFAs included in this study were retrieved 
from the pathology archives of a cancer centre, which might 
have contributed to the high frequency of co- occurrent inva-
sive and/or in situ carcinomas at the time of the diagnosis of 
CFA. Given the scope of this study, we could not determine 
the prognostic significance of MED12 exon 2 mutations and 
its association with the presence of co- occurrent invasive and/
or in situ carcinomas identified in our cohort. Further studies 
to assess the impact of MED12 exon 2 mutations in CFAs 
in the risk of development of breast cancer are warranted. 
Despite these limitations, here we demonstrated that CFAs 
harbour MED12 exon 2 mutations in the stromal component, 
akin to other histologic variants of FAs. At variance with 
conventional FAs, however, the frequency of MED12 exon 2 
mutations in CFAs appears to be lower than that of conven-
tional FAs. Further studies are warranted to define the genetic 
underpinning of MED12 wild- type CFAs.
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Supplementary Figure 1. Histologic features of complex fibroadenomas of the breast. 
Representative hematoxylin and eosin micrographs of complex fibroadenomas lacking MED12 
exon 2 mutations included in the study. Scale bar, 2mm. Corresponding sample IDs are indicated 





Supplementary Table S1: Primers used for Sanger sequencing. 
Supplementary Table S2. Clinicopathological characteristics, MED12 exon 2 and TERT 
promoter status of the complex fibroadenomas of the breast included in this study. 
Supplementary Table S3. MED12 exon 2 mutations identified in the complex fibroadenomas of 
the breast and their predicted pathogenicity. 
Supplementary Table S4. MED12 exon 2, TERT promoter and PIK3CA exon 9 and exon 20 
status in the complex fibroadenomas of the breast subjected to laser capture microdissection of 
the epithelial and stromal components. 
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Supplementary Methods 
Laser capture microdissection  
Eight-μm-thick FFPE sections of cases CFA18 and CFA22 were cut using a microtome cryostat 
(Leica) and mounted onto Arcturus PEN Membrane glass slides (Life Technologies). Slides were 
dehydrated and stained with hematoxylin. Laser capture microdissection was performed using an 
LMD 6500 instrument (Leica Microsystem). The stromal and epithelial components of a given 
case were outlined using the associated software and then captured separately using an infrared 
capture laser. DNA from the microdissected components was extracted using the DNeasy Blood 
and Tissue Kit (Qiagen) according to manufacturer’ instructions and subjected to mutation 
screening described below. 
 
PCR amplification and Sanger sequencing 
Putative somatic mutations in selected genes of interest were investigated by Sanger sequencing. 
PCR amplification of 10ng of genomic DNA was performed using the AmpliTaq 360 Master Mix 
Kit (Life Technologies) as previously described.1,2 PCR products were purified (ExoSAP-IT, 
Thermo Fisher Scientific) and subjected to Sanger sequencing encompassing MED12 exon 2, 
TERT promoter hotspot locus and PIK3CA exons 9 and 20 (Supplementary Table S1). All 
analyses were performed in duplicate. 
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Pathology 2019; 72; 258-262. 
2. Piscuoglio S, Ng CK, Murray M et al. Massively parallel sequencing of phyllodes 
tumours of the breast reveals actionable mutations, and TERT promoter hotspot 
mutations and TERT gene amplification as likely drivers of progression. The Journal of 
Pathology 2016; 238; 508-518. 
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Gene Forward Reverse 
MED12 exon 2 TGTTCTACACGGAACCCTCCTC CTGGGCAAATGCCAATGAGAT 
TERT promoter CCAGGGCTTCCCACGTGC ACTGGGGACCCGGGCACC 
PIK3CA exon 9 CTGTGAATCCAGAGGGGAAA GCACTTACCTGTGACTCCATAGAA 
PIK3CA exon 20 CTCAATGATGCTTGGCTCTG TGGAATCCAGAGTGAGCTTTC 
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Supplementary Table S2. Clinicopathological characteristics, MED12 exon 2 mutations and 


















CFA 1 54 Post Y Y NA  WT 
CFA 2 67 Post  Y NA  WT 
CFA 4 62 Post  Y 1  WT 
CFA 5 39 Pre Y Y NA  WT 
CFA 6 41 Pre  Y 1.5  WT 
CFA 7 36 Pre  Y NA c.107T>G WT 
CFA 8 63 Post Y Y 2.1  WT 
CFA 9 47 Pre Y Y NA  WT 
CFA 10 52 Pre Y Y NA  WT 
CFA 11 63 Post Y Y NA  WT 
CFA 13 33 Pre Y Y NA  WT 
CFA 16 33 Pre Y Y NA  WT 
CFA 17 82 Post Y Y NA  WT 
CFA 18 41 Pre Y Y NA c.130G>A WT 
CFA 19 45 Pre  Y 0.9  WT 
CFA 21 37 Pre Y Y 1.8  WT 
CFA 22 52 Peri Y Y 1.6 c.130G>A WT 
CFA 24 48 Pre Y Y NA   WT 
NA, not available; WT, wild type     
 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Clin Pathol
 doi: 10.1136/jclinpath-2020-207062–4.:10 2020;J Clin Pathol, et al. da Silva EM
 5 
Supplementary Table S3. MED12 exon 2 non-synonymous somatic mutations identified in the 
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deleterious Not provided COSM131590 
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Supplementary Table S4. MED12 exon 2, TERT promoter and PIK3CA exon 9 and exon 20 
status in the complex fibroadenomas of the breast subjected to laser capture microdissection of 









Sample ID Component MED12 exon 2 TERT promoter PIK3CA exon 9 PIK3CA exon 20 
CFA18 
Stroma p.G44S WT WT WT 
Epithelium WT WT WT WT 
CFA22 
Stroma p.G44S WT WT WT 
Epithelium WT WT WT WT 




     
   
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Clin Pathol































BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Clin Pathol
 doi: 10.1136/jclinpath-2020-207062–4.:10 2020;J Clin Pathol, et al. da Silva EM
